UPDATED May 03, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$734.97 | 0.2% | 71.8% | US$661.8b | US$848.35 | PE107.8x | E27.0% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$492.45 | -0.6% | -0.4% | US$453.6b | US$567.36 | PE29.5x | E19.5% | 1.5% | Healthcare | ||
JNJ | US$149.27 | 2.1% | -8.2% | US$359.2b | US$173.26 | PE21x | E7.0% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$127.51 | -2.8% | 8.4% | US$323.0b | US$141.64 | PE140.1x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$163.79 | 2.6% | 10.6% | US$290.0b | US$182.31 | PE48.7x | E23.3% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£120.50 | 0.5% | 1.1% | UK£186.8b | UK£131.66 | PE37x | E16.5% | 2.1% | Pharmaceuticals & Biotech | ||
TMO | US$572.38 | -0.2% | 4.8% | US$218.1b | US$625.47 | PE36.2x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$105.90 | -1.5% | -4.8% | US$183.8b | US$126.09 | PE32.8x | E11.3% | 2.1% | Healthcare | ||
DHR | US$248.38 | 0.7% | 2.5% | US$182.8b | US$272.68 | PE45.2x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$311.29 | 15.3% | 31.6% | US$167.0b | US$311.27 | PE44.4x | E18.9% | 2.9% | Pharmaceuticals & Biotech | ||
PFE | US$27.81 | 9.5% | -27.7% | US$157.5b | US$31.89 | PS2.9x | E28.9% | 6.0% | Pharmaceuticals & Biotech | ||
ISRG | US$381.36 | 1.6% | 25.1% | US$134.0b | US$420.38 | PE68.1x | E11.6% | n/a | Healthcare | ||
SYK | US$328.45 | -2.1% | 15.4% | US$124.2b | US$372.35 | PE37.2x | E10.5% | 1.0% | Healthcare | ||
ELV | US$526.96 | -1.9% | 13.5% | US$122.2b | US$603.15 | PE19.6x | E12.4% | 1.2% | Healthcare | ||
MDT | US$81.69 | 2.4% | -9.3% | US$107.4b | US$94.77 | PE25.8x | E9.7% | 3.4% | Healthcare | ||
BSX | US$72.85 | -0.4% | 41.3% | US$105.9b | US$81.00 | PE60.7x | E18.1% | n/a | Healthcare | ||
REGN | US$957.00 | 8.4% | 25.6% | US$105.4b | US$1,033.38 | PE27.3x | E12.1% | n/a | Pharmaceuticals & Biotech | ||
VRTX | US$401.08 | 0.9% | 15.2% | US$103.7b | US$460.23 | PE28.6x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
CI | US$341.50 | -3.7% | 31.0% | US$97.7b | US$389.18 | PE26.8x | E18.6% | 1.6% | Healthcare | ||
GSK | UK£17.34 | 4.9% | 18.5% | UK£70.7b | UK£20.20 | PE15.8x | E11.9% | 3.3% | Pharmaceuticals & Biotech | ||
BMY | US$43.99 | -1.9% | -35.4% | US$88.6b | US$53.32 | PS2x | E43.1% | 5.5% | Pharmaceuticals & Biotech | ||
CSL | AU$275.80 | 0.9% | -8.4% | AU$133.3b | AU$306.40 | PE35.5x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
HCA | US$307.76 | 0.3% | 10.7% | US$81.7b | US$344.35 | PE14.9x | E6.0% | 0.9% | Healthcare | ||
GILD | US$64.78 | -1.0% | -18.8% | US$81.5b | US$83.46 | PE166.6x | E36.7% | 4.8% | Pharmaceuticals & Biotech |